The diagnosis and management of inhalation injury

An evidence based approach

C. J. Deutsch, A. Tan, S. Smailes, Peter Dziewulski

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Smoke inhalation injury (II) is an independent risk factor for mortality in burns and its management is inherently complex. We aim to make recommendations for best practice in managing II and its sequelae by reviewing all available current evidence in order to provide an evidence-based approach. Methods: We conducted a systematic search of the Cochrane database and Embase using PRISMA guidelines with no patient population exclusion criteria. Published work was reviewed and evidence levels graded. Results: We identified 521 abstracts for inclusion. Of the 84 articles identified for secondary review, 28 papers were excluded leaving 56 papers suitable for final inclusion. Conclusions: We are able to identify a number of strategies in both diagnosis and treatment of II that have support in the published literature, including the role of bronchoscopy, permissive hypercapnia, nebulized heparin and hydroxycobalamin. Other strategies have not been shown to be harmful, but their efficacy is also not firmly established, such as high frequency oscillatory ventilation and exogenous surfactant. Prophylactic antibiotics and corticosteroids are not recommended. In general, published evidence for II is mostly Level 3 or below, due to a noticeable lack of large-scale human studies. This represents a challenge for evidence-based burns practice as a whole.

Original languageEnglish (US)
Pages (from-to)1040-1051
Number of pages12
JournalBurns
Volume44
Issue number5
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Inhalation
Burns
Wounds and Injuries
Smoke Inhalation Injury
Hydroxocobalamin
High-Frequency Ventilation
Hypercapnia
Evidence-Based Practice
Bronchoscopy
Practice Guidelines
Surface-Active Agents
Heparin
Adrenal Cortex Hormones
Databases
Guidelines
Anti-Bacterial Agents
Mortality
Population
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Critical Care and Intensive Care Medicine

Cite this

The diagnosis and management of inhalation injury : An evidence based approach. / Deutsch, C. J.; Tan, A.; Smailes, S.; Dziewulski, Peter.

In: Burns, Vol. 44, No. 5, 01.08.2018, p. 1040-1051.

Research output: Contribution to journalReview article

Deutsch, C. J. ; Tan, A. ; Smailes, S. ; Dziewulski, Peter. / The diagnosis and management of inhalation injury : An evidence based approach. In: Burns. 2018 ; Vol. 44, No. 5. pp. 1040-1051.
@article{6c5f0f2921954224931a55c867a5bc72,
title = "The diagnosis and management of inhalation injury: An evidence based approach",
abstract = "Introduction: Smoke inhalation injury (II) is an independent risk factor for mortality in burns and its management is inherently complex. We aim to make recommendations for best practice in managing II and its sequelae by reviewing all available current evidence in order to provide an evidence-based approach. Methods: We conducted a systematic search of the Cochrane database and Embase using PRISMA guidelines with no patient population exclusion criteria. Published work was reviewed and evidence levels graded. Results: We identified 521 abstracts for inclusion. Of the 84 articles identified for secondary review, 28 papers were excluded leaving 56 papers suitable for final inclusion. Conclusions: We are able to identify a number of strategies in both diagnosis and treatment of II that have support in the published literature, including the role of bronchoscopy, permissive hypercapnia, nebulized heparin and hydroxycobalamin. Other strategies have not been shown to be harmful, but their efficacy is also not firmly established, such as high frequency oscillatory ventilation and exogenous surfactant. Prophylactic antibiotics and corticosteroids are not recommended. In general, published evidence for II is mostly Level 3 or below, due to a noticeable lack of large-scale human studies. This represents a challenge for evidence-based burns practice as a whole.",
author = "Deutsch, {C. J.} and A. Tan and S. Smailes and Peter Dziewulski",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.burns.2017.11.013",
language = "English (US)",
volume = "44",
pages = "1040--1051",
journal = "Burns",
issn = "0305-4179",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - The diagnosis and management of inhalation injury

T2 - An evidence based approach

AU - Deutsch, C. J.

AU - Tan, A.

AU - Smailes, S.

AU - Dziewulski, Peter

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Introduction: Smoke inhalation injury (II) is an independent risk factor for mortality in burns and its management is inherently complex. We aim to make recommendations for best practice in managing II and its sequelae by reviewing all available current evidence in order to provide an evidence-based approach. Methods: We conducted a systematic search of the Cochrane database and Embase using PRISMA guidelines with no patient population exclusion criteria. Published work was reviewed and evidence levels graded. Results: We identified 521 abstracts for inclusion. Of the 84 articles identified for secondary review, 28 papers were excluded leaving 56 papers suitable for final inclusion. Conclusions: We are able to identify a number of strategies in both diagnosis and treatment of II that have support in the published literature, including the role of bronchoscopy, permissive hypercapnia, nebulized heparin and hydroxycobalamin. Other strategies have not been shown to be harmful, but their efficacy is also not firmly established, such as high frequency oscillatory ventilation and exogenous surfactant. Prophylactic antibiotics and corticosteroids are not recommended. In general, published evidence for II is mostly Level 3 or below, due to a noticeable lack of large-scale human studies. This represents a challenge for evidence-based burns practice as a whole.

AB - Introduction: Smoke inhalation injury (II) is an independent risk factor for mortality in burns and its management is inherently complex. We aim to make recommendations for best practice in managing II and its sequelae by reviewing all available current evidence in order to provide an evidence-based approach. Methods: We conducted a systematic search of the Cochrane database and Embase using PRISMA guidelines with no patient population exclusion criteria. Published work was reviewed and evidence levels graded. Results: We identified 521 abstracts for inclusion. Of the 84 articles identified for secondary review, 28 papers were excluded leaving 56 papers suitable for final inclusion. Conclusions: We are able to identify a number of strategies in both diagnosis and treatment of II that have support in the published literature, including the role of bronchoscopy, permissive hypercapnia, nebulized heparin and hydroxycobalamin. Other strategies have not been shown to be harmful, but their efficacy is also not firmly established, such as high frequency oscillatory ventilation and exogenous surfactant. Prophylactic antibiotics and corticosteroids are not recommended. In general, published evidence for II is mostly Level 3 or below, due to a noticeable lack of large-scale human studies. This represents a challenge for evidence-based burns practice as a whole.

UR - http://www.scopus.com/inward/record.url?scp=85041634740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041634740&partnerID=8YFLogxK

U2 - 10.1016/j.burns.2017.11.013

DO - 10.1016/j.burns.2017.11.013

M3 - Review article

VL - 44

SP - 1040

EP - 1051

JO - Burns

JF - Burns

SN - 0305-4179

IS - 5

ER -